Elsewhere: [math people] [google] [google scholar]

- Inferiority index and margin in noninferiority trials. Statistics in Biopharmaceutical Research 2011. 3:288-301 .
- Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine 2004. 23:2771-2774 .
- Evaluation of health-related quality-of-life measures in oncology drug product applications: Issues and concerns#. Journal of Biopharmaceutical Statistics 2004. 14:23-30 .
- Evaluation of health-related quality-of-life measures in oncology drug product applications: Issues and concerns. Journal of Biopharmaceutical Statistics 2004. 14:23-30 .
- Design and analysis of non-inferiority mortality trials in oncology†‡. Statistics in Medicine 2003. 22:- .
- On sample size and inference for two-stage adaptive designs. Biometrics 2001. 57:172-177 .
- The attractiveness of the concept of a prospectively designed two-stage clinical trial. Journal of Biopharmaceutical Statistics 1999. 9:537-547 .
- Clinical decision rules and statistical support structures -- A novel approach to handling the multiple endpoints problem. .
- Multiple testings: Multiple comparisons and multiple endpoints. Drug Information Journal 1998. 32:1347-1362 .
- Application of bootstrap in handling multiple endpoints. .
- Statistical issues in measuring the agreement between diagnostic methods for disease detection. .
- On the assessment of tolerance to nitrate therapy in the treatment of angina pectoris. .
- Efficacy evaluation for monotherapies in two-by-two factorial trials. Biometrics 1995. 51:1483-1493 .
- Blends of statistical designs for dose-response studies. Communications in Statistics: Theory and Methods 1994. 23:341-360 .
- On some statistical methods for analysis of combination drug studies. Communications in Statistics: Theory and Methods 1994. 23:361-376 .
- Dose response studies and special populations. .
- Using the GEE method to construct linear models for ordinal responses. .
- Comparing properties of various trough/peak ratio estimators. .
- Efficacy evaluation for monotherapies in two-by-two factorial trials. .
- A new statistical method for testing a combination therapy's superiority to both of its components. .
- A preliminary assessment of two evolving CANDA review systems from the perspective of FDA statistical reviewers. .
- Testing for the existence of a dose combination beating its components. .
- Designing a clinical trial to demonstrate prevention of ulcer recurrence: Modelling simulation approaches. Statistics in Medicine 1988. 7:877-888 .
- A design problem in ulcer prevention trials. .
- Design considerations for some combination drug trials in the treatment for hypertension. .